EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The promise of antibody-oligonucleotide conjugates for neurological diseases

Kerstin Hofer

Bioconjugation Insights · 2025

DOI: 10.18609/bci.2025.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugation Insights, 2025. Verfasst von Kerstin Hofer. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

“To fully unlock their potential, there are a few key breakthroughs that are going to be critical.”Lauren Coyle, Launch Commissioning Editor, Bioconjugation Insights, speaks with Kerstin Hofer, Science and People Lead, Roche, about the evolving application of antibody-oligonucleotide conjugates in neurology. She highlights their design, delivery challenges across the blood–brain barrier, and potential to transform CNS diseases.

Zitieren

APA

Hofer, K. (2025). The promise of antibody-oligonucleotide conjugates for neurological diseases. Bioconjugation Insights. https://doi.org/10.18609/bci.2025.018

Vancouver

Hofer K. The promise of antibody-oligonucleotide conjugates for neurological diseases. Bioconjugation Insights. 2025. doi:10.18609/bci.2025.018

BibTeX
@article{Hofer2025,
  author = {Hofer, Kerstin},
  title = {The promise of antibody-oligonucleotide conjugates for neurological diseases},
  journal = {Bioconjugation Insights},
  year = {2025},
  doi = {10.18609/bci.2025.018}
}
Kostenlos starten →